HGS/GSK's Benlysta Gets Advisory Panel Backing For Lupus Labeling That Reflects Trials' Limitations

Arthritis Advisory Committee says belimumab efficacy is not shown for full spectrum of the disease, so the biologic should go to market with appropriate caveats.